Dysregulated expression of SKP2 and its role in hematological malignancies

Michal Kulinski, Iman W. Achkar, Mohammad Haris, Said Dermime, Ramzi M. Mohammad, Shahab Uddin

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

S-phase kinase-associated protein 2 (SKP2) is a well-studied F-box protein and a critical part of the Skp1-Cul1-Fbox (SCF) E3 ligase complex. It controls cell cycle by regulating the expression level of p27 and p21 through ubiquitination and proteasomal degradation. SKP2-mediated loss of p27Kip1 is associated with poor clinical outcome in various types of cancers including hematological malignancies. It is however well established that SKP2 is an oncogene, and its targeting may be an attractive therapeutic strategy for the management of hematological malignancies. In this article, we have highlighted the recent findings from our group and other investigators regarding the role of SKP2 in the pathogenesis of hematological malignancies.

Original languageEnglish
Pages (from-to)1051-1063
Number of pages13
JournalLeukemia and Lymphoma
Volume59
Issue number5
DOIs
Publication statusPublished - 4 May 2018

    Fingerprint

Keywords

  • hematological malignancies
  • p27Kip1
  • Proteasome pathways
  • proto-oncogene
  • SKP2

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Kulinski, M., Achkar, I. W., Haris, M., Dermime, S., Mohammad, R. M., & Uddin, S. (2018). Dysregulated expression of SKP2 and its role in hematological malignancies. Leukemia and Lymphoma, 59(5), 1051-1063. https://doi.org/10.1080/10428194.2017.1359740